Skip to content

Study of the Role of Innate Lymphoid Cells and Natural Killer Cells in Immune Activation of Vitiligo - INNATE Vitiligo

Study of the Role of Innate Lymphoid Cells and Natural Killer Cells in Immune Activation of Vitiligo

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03859518
Acronym
INNATEvitiligo
Enrollment
20
Registered
2019-03-01
Start date
2016-07-31
Completion date
2019-12-31
Last updated
2019-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vitiligo

Brief summary

The cohort included only major patients with non-segmental vitiligo and no other autoimmune or inflammatory associated diseases (except thyroiditis). Control subjects should have no autoimmune or inflammatory diseases. Patients and controls should not take treatment with corticosteroids or other potentially immunomodulatory therapies. Patients and controls are recruited in the Dermatology Department of the University Hospital of Nice and the Hospital of Fréjus. The investigators have already initiated the collection of tissues and blood from patients and control subjects and we have succeeded in isolating ILCs and NKs from a blood volume of 50ml. We were able to sort the ILC subpopulations. Early data suggest an increase in Natural Killer (NK) and Innate Lymphoïdes Cells 1 (ILC1) in the blood of vitiligo patients compared to control subjects. The investigators also managed to extract the melanocytes from the skin biopsies of the first patients and control subjects.

Detailed description

The investigators want study the presence and type of ILC and NK in the blood and skin of vitiligo patients compared to control subjects.

Interventions

OTHERblood and skin samples

To study the presence and type of ILC and NK in the blood and skin of vitiligo patients compared to control subjects.

Sponsors

Institut National de la Santé Et de la Recherche Médicale, France
CollaboratorOTHER_GOV
Centre Hospitalier Universitaire de Nice
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

vitiligo subjects : * patients in the cohort with non-segmental vitiligo * without other autoimmune or inflammatory diseases associated control subjects : * subject without autoimmune or inflammatory disease

Design outcomes

Primary

MeasureTime frameDescription
study the presence and type of ILC and NK in the blood and skin1 dayCompare vitiligo patients to control subjects.
study the presence and type of ILC and NK in the skin1 dayCompare vitiligo patients to control subjects.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026